Popular on s4story
- Bald Guy Greetings Launches Bold New Postcard Line Celebrating Over-the Top (and Often Delusional) Confidence
- DMV Native And Eight-Time Emmy Winner Justin W. Brown Directs A Moving Tribute To A Community's Legacy
- Two exciting new fantasy & adventure books are published
- Charming Ogawamachi Town, in Saitama Prefecture, Japan, Announces Festivals for 2025
- Jumpstart Summer Adventures at the Y
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- Transform Your Home with Expert Kitchen Remodeling Near Bloomington, MN
- Homeowners Turn to Smart Kitchen Remodeling Companies in Fort Lauderdale
- Robotphoenix to Jointly Exhibit with DERI SRL at IPACK-IMA 2025 in Milan
- Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD: NRx: (Stock Symbol: NRXP)
Similar on s4story
- Barcelona-based Neurosurgical Specialist Awarded Designation of International Center of Excellence for Ehlers Danlos Syndrome
- Pregis Expands Multi-Layer Technology for High-Performance Barrier Films at Anderson Facility
- New Professional Association to Study Principles of Hospitality Applied to the Delivery of Healthcare
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
- New WHO Mental Health Guidelines Condemn Coercive Psychiatry
- Keenan's Caring Konnections, LLC
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
OncoBeta introduces Rhenium-SCT for non-melanoma skin cancer patients at Hospital Universitario 12 de Octubre
S For Story/10629063
MADRID - s4story -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, today announced Hospital Universitario 12 de Octubre, in Madrid, has treated its first patient with Rhenium-SCT® (skin cancer therapy) – and is expected to continue offering this therapy for patients with non-melanoma skin cancers (NMSCs).
Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."
New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.
"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.
Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".
More on S For Story
___
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
More on S For Story
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.8
References
Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."
New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.
"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.
Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".
More on S For Story
- Barcelona-based Neurosurgical Specialist Awarded Designation of International Center of Excellence for Ehlers Danlos Syndrome
- Author Makeda Releases New Book Built Not Bought—A Powerful Guide to Creating an Intentional Life
- Pregis Expands Multi-Layer Technology for High-Performance Barrier Films at Anderson Facility
- New Professional Association to Study Principles of Hospitality Applied to the Delivery of Healthcare
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
___
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
More on S For Story
- Bone Flute: A Woman Speaks Launches
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms
- La'Nardo Myrick Sr. Honors Women's Strength with New Poetry Collection
- Hannah Jessen Conway's Children's Book "Love Sounds Like" Wins Prestigious First Horizon Award
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.8
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).
Source: OncoBeta GmbH
0 Comments
Latest on S For Story
- Chapter 3: The Molestation from A Letter to Pawtone
- Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
- Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Former Orange County Commissioner Homer Hartage Announces Heartwarming New Children's Picture Book
- Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
- Two exciting new fantasy & adventure books are published
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- "The Eyes Have It" a Short Story by Philip K. Dick Now Available on Audiobook
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Fairfield Inn by Marriott Scottsdale Old Town Opens
- Make Cursive Fun Again with the New Writing Scholars Activity Book
- Bilingual Learning Made Fun: Tagalog-English Body Parts Book for Kids
- "The Memory Box, Charlotte's Big Surprise" Now Available at Barnes & Noble"
- Pelican Reef Group Announces Grand Opening of New High Point Showroom – IHFC Building H-621 & Event April 27th, 2025
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing